Addex Therapeutics Ltd (ADXN): Business Model Canvas

Key Partnerships

At Addex Therapeutics Ltd, we understand the importance of forming strong partnerships to drive innovation and maximize our impact in the pharmaceutical industry. Our key partnerships include:

• Collaborations with pharma and biotech companies: We establish partnerships with pharmaceutical and biotechnology companies to leverage their expertise, resources, and market access. By collaborating with industry leaders, we can accelerate the development and commercialization of our products.
• Academic and research institutions: We collaborate with academic and research institutions to access cutting-edge scientific expertise and technologies. These partnerships enable us to stay at the forefront of scientific advancements and develop novel therapies for unmet medical needs.
• Strategic alliances for technology sharing: We form strategic alliances with other companies to share technologies, knowledge, and resources. By pooling our resources and expertise with strategic partners, we can achieve mutual benefits and advance our research and development efforts.
• Outsourcing partners for clinical trials: We partner with outsourcing companies to conduct clinical trials efficiently and cost-effectively. These partnerships allow us to focus on our core competencies while leveraging the expertise of outsourcing partners to conduct clinical trials in compliance with regulatory requirements.

Key Activities

Research and development of allosteric modulators: Addex Therapeutics Ltd focuses on the discovery and development of allosteric modulators, which are small molecules that target specific proteins to regulate their activity. This involves a combination of in vitro and in vivo studies to identify promising compounds that can modulate the activity of target proteins in a specific way.

Clinical trials and drug testing: Once a potential allosteric modulator is identified, Addex Therapeutics conducts clinical trials to evaluate the safety and efficacy of the compound in humans. This involves designing and implementing rigorous testing protocols to gather data on the compound's pharmacokinetics, pharmacodynamics, and potential side effects.

Regulatory compliance and submissions: Addex Therapeutics works closely with regulatory agencies such as the FDA and EMA to ensure that its clinical trials and drug development programs comply with all relevant guidelines and regulations. This includes submitting detailed documentation on the compound's safety and efficacy profile, as well as addressing any concerns or requests for additional information from regulatory authorities.

Intellectual property management: Addex Therapeutics places a high priority on protecting its intellectual property through patents, trademarks, and other forms of legal protection. This involves conducting comprehensive searches to identify existing patents and ensuring that the company's own innovations are properly documented and filed for protection.

Key Resources

Scientific and research expertise: Addex Therapeutics Ltd benefits from its team of experienced scientists and researchers who are experts in allosteric modulation. This expertise allows the company to develop novel therapies with a deep understanding of the underlying mechanisms.

Proprietary technology in allosteric modulation: Addex Therapeutics Ltd holds the rights to proprietary technology that allows for the modulation of allosteric sites on proteins. This technology gives the company a unique advantage in drug development, allowing for the creation of more targeted and efficacious therapies.

Clinical trial data and infrastructure: The company has a wealth of clinical trial data from previous studies, as well as the infrastructure in place to conduct future trials. This data and infrastructure are crucial for advancing the development of new therapies and gaining regulatory approval.

Licenses for drug development and commercialization: Addex Therapeutics Ltd has secured licenses for the development and commercialization of certain drugs, allowing the company to bring these therapies to market once they have been proven safe and effective. These licenses are valuable assets that contribute to the company's overall success.

Value Propositions

Addex Therapeutics Ltd (ADXN) offers several key value propositions in the biopharmaceutical industry:

• Innovative allosteric modulators: Addex Therapeutics focuses on developing innovative allosteric modulators that have the potential to significantly improve drug efficacy compared to traditional orthosteric ligands. By targeting allosteric sites on a receptor, Addex Therapeutics' compounds can fine-tune the signaling pathways of a target protein, leading to more precise and tailored therapeutic effects.
• Targeted therapies with reduced side effects: The company's focus on allosteric modulation allows for the development of more targeted therapies with reduced side effects. By selectively modulating the activity of a target protein, Addex Therapeutics can minimize off-target effects, leading to better treatment outcomes and improved patient safety.
• Partnerships for co-development and licensing: Addex Therapeutics collaborates with pharmaceutical partners for co-development and licensing opportunities. By leveraging its expertise in allosteric modulation and drug discovery, the company can create valuable partnerships that accelerate the development and commercialization of novel therapies.
• Commitment to addressing unmet medical needs in neurological disorders: Addex Therapeutics is dedicated to addressing unmet medical needs in neurological disorders through the development of innovative therapies. By focusing on conditions such as Parkinson's disease, epilepsy, and multiple sclerosis, the company aims to make a meaningful impact on patient care and quality of life.

Customer Relationships

At Addex Therapeutics Ltd (ADXN), we prioritize building strong relationships with our customers to ensure the success of our business model. Here are some key ways we engage with our customers:

• Engagement through scientific conferences and publications: We actively participate in industry conferences and publish research findings in leading scientific journals to engage with key stakeholders in the healthcare and pharmaceutical industries. This helps us showcase our innovations and build credibility within the scientific community.
• Collaboration with healthcare professionals and institutions: We work closely with healthcare professionals and institutions to better understand the needs of patients and healthcare providers. By collaborating with key opinion leaders and experts in various fields, we can tailor our products and solutions to meet the specific needs of our customers.
• Direct support for clinical trial participants: We provide direct support to participants in our clinical trials to ensure a positive experience and compliance with study protocols. This includes education about the trial, monitoring for adverse events, and addressing any concerns or questions that participants may have. Our focus on patient-centricity helps us build trust and loyalty with clinical trial participants.
• Long-term partnerships with pharmaceutical companies: We establish long-term partnerships with pharmaceutical companies to collaborate on research, development, and commercialization efforts. These partnerships enable us to leverage our strengths and resources to bring innovative products to market more efficiently and effectively. By working closely with pharmaceutical partners, we can access new markets, expand our product portfolio, and drive growth for our business.

Channels

Addex Therapeutics Ltd utilizes a variety of channels to reach its target audience and distribute its products and services. These channels include:

• Direct engagement with pharmaceutical companies: Addex Therapeutics Ltd actively seeks out partnerships and licensing opportunities with pharmaceutical companies to further develop and commercialize its products.
• Distribution through healthcare and medical channels: The company leverages existing healthcare and medical channels to distribute its products to healthcare professionals and patients.
• Online platforms for publishing research findings: Addex Therapeutics Ltd utilizes online platforms to publish its research findings, reaching a wider audience and establishing itself as a thought leader in the industry.
• Participation in industry conferences and seminars: The company regularly participates in industry conferences and seminars to showcase its products, network with potential partners, and stay up-to-date on the latest developments in the field.

By utilizing a multi-faceted approach to distribution and communication, Addex Therapeutics Ltd ensures that its products and services reach the right audience and that it remains at the forefront of the industry.

Customer Segments

Addex Therapeutics Ltd targets several key customer segments in the pharmaceutical and healthcare industries:

• Pharmaceutical companies: Addex offers a range of drug candidates and technologies for licensing to pharmaceutical companies looking to expand their pipeline in the field of neurological and psychiatric disorders.
• Research institutions: Addex collaborates with research institutions to advance scientific knowledge and develop novel therapies for neurological and psychiatric disorders.
• Patients: Addex focuses on developing treatments for patients suffering from neurological and psychiatric disorders, addressing unmet medical needs in these areas.
• Healthcare providers: Addex provides innovative therapies to healthcare providers, offering new treatment options for patients with neurological and psychiatric disorders.

Value Proposition

Addex Therapeutics Ltd offers a unique value proposition to its customers:

• Novel drug candidates: Addex's pipeline includes innovative drug candidates targeting neurological and psychiatric disorders, providing new treatment options for patients.
• Cutting-edge technology: Addex uses state-of-the-art technologies to develop drugs with high therapeutic potential and improved safety profiles.
• Collaborative partnerships: Addex collaborates with pharmaceutical companies and research institutions to accelerate drug development and bring new therapies to market.
• Patient-centric approach: Addex focuses on meeting the needs of patients with neurological and psychiatric disorders, striving to improve their quality of life through innovative treatments.

Channels

Addex Therapeutics Ltd uses multiple channels to reach its target customers:

• Direct sales: Addex's sales team works directly with pharmaceutical companies and healthcare providers to promote and license its drug candidates.
• Online platforms: Addex utilizes online platforms and digital marketing to reach a wider audience of potential collaborators and patients.
• Events and conferences: Addex participates in industry events and conferences to network with key stakeholders and showcase its latest research and developments.
• Partnership agreements: Addex forms strategic partnerships with other biotech companies, research institutions, and healthcare organizations to expand its reach and access new markets.

Cost Structure

Addex Therapeutics Ltd (ADXN) has a cost structure that is primarily focused on research and development (R&D) activities. The company invests heavily in developing new drug candidates, conducting preclinical and clinical trials, and obtaining regulatory approvals. These costs can be significant, as the company strives to bring innovative therapies to market that can address unmet medical needs.

In addition to R&D expenses, Addex Therapeutics Ltd also incurs costs related to conducting clinical trials. These costs can include patient recruitment, data collection and analysis, and monitoring trial progress. Clinical trials are essential for demonstrating the safety and efficacy of new drug candidates before they can be approved for use in patients.

Regulatory and compliance expenses are another important component of Addex Therapeutics Ltd's cost structure. The company must adhere to strict regulations set forth by health authorities in order to bring new drugs to market. This involves submitting data to regulatory agencies, meeting safety and quality standards, and obtaining approvals for clinical trials and drug marketing.

Operational and administrative costs are also necessary for Addex Therapeutics Ltd to function effectively. These costs can include salaries for employees, rent for office and laboratory space, utilities, and other general expenses. Operational and administrative costs are essential for the day-to-day functioning of the company and supporting its R&D activities.

• R&D expenses
• Clinical trial costs
• Regulatory and compliance expenses
• Operational and administrative costs

Revenue Streams

Addex Therapeutics Ltd generates revenue through various streams, which are essential for the sustainability and growth of the company. These revenue streams include:

• Licensing fees from pharmaceutical companies: Addex Therapeutics Ltd earns revenue through licensing agreements with pharmaceutical companies for the use of their proprietary technologies and drug candidates. These licensing fees provide a steady source of income for the company.
• Funding from research grants and partnerships: The company also generates revenue from research grants and collaborations with academic institutions, biotechnology companies, and government agencies. These partnerships not only provide financial support but also help in advancing the company's research and development efforts.
• Revenue from patented drug sales: Addex Therapeutics Ltd earns revenue from the sale of patented drugs that have been developed through their research and development programs. These patented drugs provide a significant source of income for the company.
• Payments for consultancy and collaboration services: In addition to licensing fees and drug sales, the company also generates revenue from consultancy services and collaborations with other companies in the pharmaceutical and biotechnology industries. These services include providing expertise in drug discovery, development, and commercialization.